Skip to main content

30.04.2024 | RESEARCH

FOXP4-AS1 promotes CD8+ T cell exhaustion and esophageal cancer immune escape through USP10-stabilized PD-L1

verfasst von: Guo-yi Shen, Yi Zhang, Rong-zhi Huang, Zhi-yong Huang, Le-yi Yang, Ding-zhu Chen, Shao-bin Yang

Erschienen in: Immunologic Research

Einloggen, um Zugang zu erhalten

Abstract

Esophageal cancer (EC) is the 9th most frequently diagnosed malignancy globally with unfavorable prognosis. Immune escape is one of the principal factors leading to poor survival, however, the mechanism underlying immune escape remains largely uninvestigated. The xenograft mouse model and EC cell-CD8+ cytotoxic T lymphocytes (CTLs) co-culture system were established. Immunohistochemistry, qRT-PCR or western blot were employed to detect the levels of long non-coding RNA (lncRNA) FOXP4-AS1, PD-L1, USP10 and other molecules. The abundance of T cells, cytokine production and cell apoptosis were monitored by flow cytometry. The viability of CTLs was assessed by Trypan blue staining. The binding between FOXP4-AS1 and USP10 was validated by RNA pull-down assay, and the interaction between USP10 and PD-L1, as well as the ubiquitination of PD-L1, were detected by co-immunoprecipitation. The elevation of FOXP4-AS1 in EC was associated with decreased CTL abundance, and upregulated PD-L1 facilitated CTL apoptosis in EC. FOXP4-AS1 accelerated EC tumor growth by decreasing the abundance of tumor infiltrating CTLs in vivo. FOXP4-AS1 inhibited the viability of CTLs and facilitated the cytotoxicity and exhaustion of CTLs. In Kyse 450 cell-CTL co-culture system, FOXP4-AS1 suppressed the viability and abundance of CTLs, and inhibited EC cell apoptosis via PD-L1. Mechanistically, FOXP4-AS1 regulated the ubiquitination of PD-L1 through deubiquitinating enzyme USP10. FOXP4-AS1 promoted CTL exhaustion and EC immune escape through USP10-stabilized PD-L1.

Highlights

  • PD-L1 facilitated CD8+ T cell apoptosis in EC.
  • Upregulated FOXP4-AS1 promoted EC tumor growth by inhibiting the viability and facilitating the cytotoxicity and exhaustion of tumor infiltrating CD8+ T cells.
  • FOXP4-AS1 suppressed the viability and abundance of CD8+ T cells through USP10-mediated deubiquitination of PD-L1.
Literatur
1.
Zurück zum Zitat Sheikh M, et al. Current status and future prospects for esophageal cancer. Cancers. 2023;15(3):765. Sheikh M, et al. Current status and future prospects for esophageal cancer. Cancers. 2023;15(3):765.
2.
Zurück zum Zitat Liang H, Fan JH, Qiao YL. Epidemiology, etiology, and prevention of esophageal squamous cell carcinoma in China. Cancer Biol Med. 2017;14(1):33–41.CrossRefPubMedPubMedCentral Liang H, Fan JH, Qiao YL. Epidemiology, etiology, and prevention of esophageal squamous cell carcinoma in China. Cancer Biol Med. 2017;14(1):33–41.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Li B, et al. Trends of esophageal cancer incidence and mortality and its influencing factors in China. Risk Manag Healthc Policy. 2021;14:4809–21.CrossRefPubMedPubMedCentral Li B, et al. Trends of esophageal cancer incidence and mortality and its influencing factors in China. Risk Manag Healthc Policy. 2021;14:4809–21.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Jiang Y, et al. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019;15(5):1111–22.CrossRefPubMedPubMedCentral Jiang Y, et al. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019;15(5):1111–22.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Li R, et al. Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment. Front Oncol. 2022;12:1096717.CrossRefPubMed Li R, et al. Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment. Front Oncol. 2022;12:1096717.CrossRefPubMed
8.
Zurück zum Zitat Vrana D, et al. From tumor immunology to immunotherapy in gastric and esophageal cancer. Int J Mol Sci. 2018;20(1):13. Vrana D, et al. From tumor immunology to immunotherapy in gastric and esophageal cancer. Int J Mol Sci. 2018;20(1):13.
10.
Zurück zum Zitat Zhang G, et al. FOXP4-AS1 may be a potential prognostic biomarker in human cancers: a meta-analysis and bioinformatics analysis. Front Oncol. 2022;12:799265.CrossRefPubMedPubMedCentral Zhang G, et al. FOXP4-AS1 may be a potential prognostic biomarker in human cancers: a meta-analysis and bioinformatics analysis. Front Oncol. 2022;12:799265.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Niu Y, et al. LncRNA FOXP4-AS1 promotes the progression of esophageal squamous cell carcinoma by interacting with MLL2/H3K4me3 to upregulate FOXP4. Front Oncol. 2021;11:773864.CrossRefPubMedPubMedCentral Niu Y, et al. LncRNA FOXP4-AS1 promotes the progression of esophageal squamous cell carcinoma by interacting with MLL2/H3K4me3 to upregulate FOXP4. Front Oncol. 2021;11:773864.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Li Y, et al. YY1-induced upregulation of FOXP4-AS1 and FOXP4 promote the proliferation of esophageal squamous cell carcinoma cells. Cell Biol Int. 2020;44(7):1447–57.CrossRefPubMed Li Y, et al. YY1-induced upregulation of FOXP4-AS1 and FOXP4 promote the proliferation of esophageal squamous cell carcinoma cells. Cell Biol Int. 2020;44(7):1447–57.CrossRefPubMed
13.
Zurück zum Zitat Jiang X, Chen ZJ. The role of ubiquitylation in immune defence and pathogen evasion. Nat Rev Immunol. 2011;12(1):35–48.CrossRefPubMed Jiang X, Chen ZJ. The role of ubiquitylation in immune defence and pathogen evasion. Nat Rev Immunol. 2011;12(1):35–48.CrossRefPubMed
16.
Zurück zum Zitat Cao YF, et al. Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma. Cell Death Differ. 2023;30(2):527–43.CrossRefPubMed Cao YF, et al. Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma. Cell Death Differ. 2023;30(2):527–43.CrossRefPubMed
17.
Zurück zum Zitat Borgmann M, Quante M. Impact of the tumor microenvironment for esophageal tumor development-an opportunity for prevention?. Cancers. 2022;14(9):2246. Borgmann M, Quante M. Impact of the tumor microenvironment for esophageal tumor development-an opportunity for prevention?. Cancers. 2022;14(9):2246.
18.
19.
Zurück zum Zitat Liao C, et al. Long non-coding RNA FOXP4-AS1 is a prognostic biomarker and associated with immune infiltrates in ovarian serous cystadenocarcinoma. Medicine. 2021;100(40):e27473.CrossRefPubMedPubMedCentral Liao C, et al. Long non-coding RNA FOXP4-AS1 is a prognostic biomarker and associated with immune infiltrates in ovarian serous cystadenocarcinoma. Medicine. 2021;100(40):e27473.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Tao L, et al. USP10 as a potential therapeutic target in human cancers. Genes. 2022;13(5):831. Tao L, et al. USP10 as a potential therapeutic target in human cancers. Genes. 2022;13(5):831.
22.
24.
Zurück zum Zitat Chen L, et al. PD-L1 expression promotes epithelial to mesenchymal transition in human esophageal cancer. Cell Physiol Biochem. 2017;42(6):2267–80.CrossRefPubMed Chen L, et al. PD-L1 expression promotes epithelial to mesenchymal transition in human esophageal cancer. Cell Physiol Biochem. 2017;42(6):2267–80.CrossRefPubMed
25.
Zurück zum Zitat Xu J, et al. Evidence that dysplasia related microRNAs in Barrett’s esophagus target PD-L1 expression and contribute to the development of esophageal adenocarcinoma. Aging. 2020;12(17):17062–78.CrossRefPubMedPubMedCentral Xu J, et al. Evidence that dysplasia related microRNAs in Barrett’s esophagus target PD-L1 expression and contribute to the development of esophageal adenocarcinoma. Aging. 2020;12(17):17062–78.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Wang H, et al. Exosomal PD-L1 confers chemoresistance and promotes tumorigenic properties in esophageal cancer cells via upregulating STAT3/miR-21. Gene Ther. 2023;30(1–2):88–100.CrossRefPubMed Wang H, et al. Exosomal PD-L1 confers chemoresistance and promotes tumorigenic properties in esophageal cancer cells via upregulating STAT3/miR-21. Gene Ther. 2023;30(1–2):88–100.CrossRefPubMed
Metadaten
Titel
FOXP4-AS1 promotes CD8+ T cell exhaustion and esophageal cancer immune escape through USP10-stabilized PD-L1
verfasst von
Guo-yi Shen
Yi Zhang
Rong-zhi Huang
Zhi-yong Huang
Le-yi Yang
Ding-zhu Chen
Shao-bin Yang
Publikationsdatum
30.04.2024
Verlag
Springer US
Erschienen in
Immunologic Research
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-024-09482-9

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Eingreifen von Umstehenden rettet vor Erstickungstod

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Real-World-Daten sprechen eher für Dupilumab als für Op.

14.05.2024 Rhinosinusitis Nachrichten

Zur Behandlung schwerer Formen der chronischen Rhinosinusitis mit Nasenpolypen (CRSwNP) stehen seit Kurzem verschiedene Behandlungsmethoden zur Verfügung, darunter Biologika, wie Dupilumab, und die endoskopische Sinuschirurgie (ESS). Beim Vergleich der beiden Therapieoptionen war Dupilumab leicht im Vorteil.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.